PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Protagonist Therapeutics, Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$134.44+5.69 (+4.42%)
Close on Oct 19, 2026
- Market cap
- $9.55B
- P/E (TTM)
- 130.5
- Dividend yield
- –
Share price
+$56.94 (+73.47%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Protagonist Therapeutics, Inc grew revenue 34.8% to $281.99M over the twelve months to Jun 30, 2026. Operating income rose 143.3% to $58.34M, moving the operating margin from 11.5% to 20.7%. Free cash flow was $130.58M, up 252.0% from a year earlier.
Revenue
$281.99M
+34.8% vs. a year earlier
Operating income
$58.34M
+143.3% vs. a year earlier
Free cash flow
$130.58M
+252.0% vs. a year earlier
EPS, diluted
$1.03
+47.1% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $9.55B
- P/E ratio
- 130.5
- Price to sales
- 33.85
- Price to book
- 11.34
- Dividend yield
- –
- Free cash flow yield
- 1.37%
Fundamentals
- Revenue
- $281.99M
- Net income
- $82.91M
- EPS, diluted
- $1.03
- Free cash flow
- $130.58M
- Book value per share
- $11.85
- Diluted shares
- 71M
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
$281.99M+34.8% YoY
Operating income
$58.34M+143.3% YoY
Net income
$82.91M+59.3% YoY
EPS, diluted
$1.03+47.1% YoY
Free cash flow
$130.58M+252.0% YoY
Reported periodTrailing twelve months